$Emergent BioSolutions (EBS.US)$ EARNINGS CALL TRANSCRIPT IM...
EARNINGS CALL TRANSCRIPT
IMPRESSIVE!
Emergent BioSolutions Inc (EBS) (Q1 2024) Earnings Call Transcript Highlights: A Strong Start ...
Thu, 2 May 2024 at 12:54 AM GMT-7
• Total Revenue: $300 million, up 83% year-over-year.
• Adjusted Gross Margin: 51%, significantly improved from 5% the previous year.
• Adjusted EBITDA: $67 million, a substantial increase from negative $102 million last year.
• Adjusted Net Income: $31 million, improved from negative $163 million in the previous year.
• Narcan Sales: $118 million, up 18% year-over-year.
• MCM Sales: $56 million, up 155% year-over-year.
• Smallpox MCM Sales: $50 million, increased by $43 million year-over-year.
• Operating Expenses: Reduced by 16% compared to the previous year.
• Net Debt Position: $827 million as of March 31, 2024.
• 2024 Revenue Guidance: $1 billion to $1.1 billion.
• 2024 Adjusted EBITDA Guidance:$125 million to $175 million.
• 2024 Total Segment Adjusted Gross Margin Guidance: 44% to 47%.
Thu, 2 May 2024 at 12:54 AM GMT-7
• Total Revenue: $300 million, up 83% year-over-year.
• Adjusted Gross Margin: 51%, significantly improved from 5% the previous year.
• Adjusted EBITDA: $67 million, a substantial increase from negative $102 million last year.
• Adjusted Net Income: $31 million, improved from negative $163 million in the previous year.
• Narcan Sales: $118 million, up 18% year-over-year.
• MCM Sales: $56 million, up 155% year-over-year.
• Smallpox MCM Sales: $50 million, increased by $43 million year-over-year.
• Operating Expenses: Reduced by 16% compared to the previous year.
• Net Debt Position: $827 million as of March 31, 2024.
• 2024 Revenue Guidance: $1 billion to $1.1 billion.
• 2024 Adjusted EBITDA Guidance:$125 million to $175 million.
• 2024 Total Segment Adjusted Gross Margin Guidance: 44% to 47%.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment